PRESTIGE BIOPHARMA
PRESTIGE BIOPHARMA IDC
PRESTIGE BIOLOGICS
Beyond technological discovery, expanding access to care for patients around the world
Innovative Drug
Development of First-in-Class therapeutics for unmet diseases
Biosimilar
Prominent Biosimilars pipelines for accelerating market access
Platform Technology
A drug delivery platform that enhances treatment convenience
Diagnostics
Diagnostics for Pancreatic cancer by detecting PAUF
Prestige Biopharma IDC Files Patent for PBP1710 Targeting Fibrotic Diseases
[KOREAN]
[ENGLISH]
Prestige Biopharma IDC Files Patent for PBP1710 Targeting Fibrotic Diseases
Prestige Biopharma IDC announced on the 22nd that it has filed a key patent application related to its investigational antibody therapeutic, PBP1710, for the treatment of fibrotic diseases.
The filed patent covers a pharmaceutical composition for the treatment or prevention of fibrotic diseases using a monoclonal antibody targeting CTHRC1 (Collagen Triple Helix Repeat Containing 1), a protein known to play a central role in fibrosis. The antibody is designed to inhibit factors critical to fibrotic progression, thereby slowing disease advancement and alleviating tissue damage, representing a novel therapeutic approach in the field.
Fibrotic diseases are widely recognized as areas of significant unmet medical need worldwide. They can affect multiple organs, including the liver, lungs, kidneys, and skin. As fibrosis progresses, normal tissue is gradually replaced by stiff fibrotic tissue, leading to progressive organ dysfunction. Once established, fibrosis is generally difficult to reverse, and effective disease-modifying treatment options remain limited.
The patented technology specifically targets and suppresses CTHRC1, a protein that accelerates fibrotic progression. By inhibiting CTHRC1, the antibody aims to prevent excessive accumulation of collagen, a key component of the extracellular matrix (ECM) involved in fibrosis, and to block the pathological activation of fibroblasts and myofibroblasts. In addition, the therapy has the potential to mitigate chronic inflammatory responses associated with fibrotic lesions and reduce the expression of related biomarkers, thereby effectively suppressing disease progression.
Sang-seok Koh, CEO of Prestige Biopharma IDC, stated, “This patent filing is a meaningful milestone that formally declares PBP1710’s unique anti-fibrotic mechanism of action and its potential as a platform technology. We will continue our research and development efforts to present a meaningful therapeutic alternative in the field of fibrotic diseases and advance toward becoming a globally innovative new drug.”
Source: Medical Today(https://www.hankyung.com/article/202601226461i)
Read Prestige news >>
